Beigene, Ltd. (NASDAQ:ONC) COO Xiaobin Wu Sells 51,921 Shares

Beigene, Ltd. (NASDAQ:ONC - Get Free Report) COO Xiaobin Wu sold 51,921 shares of Beigene stock in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $281.40, for a total value of $14,610,569.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Xiaobin Wu also recently made the following trade(s):

• On Wednesday, March 5th, Xiaobin Wu sold 51,921 shares of Beigene stock. The shares were sold at an average price of $261.59, for a total transaction of $13,582,014.39.
• On Thursday, February 20th, Xiaobin Wu sold 21,267 shares of Beigene stock. The shares were sold at an average price of $240.07, for a total transaction of $5,105,568.69.
• On Tuesday, February 18th, Xiaobin Wu sold 30,654 shares of Beigene stock. The stock was sold at an average price of $240.74, for a total value of $7,379,643.96.

Beigene Stock Performance

ONC stock traded down $11.13 during midday trading on Tuesday, reaching $209.41. The company's stock had a trading volume of 611,456 shares, compared to its average volume of 469,630. The stock has a market cap of $20.67 billion, a price-to-earnings ratio of -25.41, a price-to-earnings-growth ratio of 7.73 and a beta of 0.49. Beigene, Ltd. has a 1 year low of $126.97 and a 1 year high of $287.88. The company has a quick ratio of 1.72, a current ratio of 1.93 and a debt-to-equity ratio of 0.05. The company's fifty day moving average price is $249.45.

Remove Ads

Beigene (NASDAQ:ONC - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($1.43) earnings per share for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.55). The company had revenue of $1.13 billion for the quarter, compared to the consensus estimate of $1.09 billion. Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%. As a group, analysts forecast that Beigene, Ltd. will post -5.82 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Sanford C. Bernstein set a $259.00 price objective on Beigene in a research report on Thursday, March 13th. Macquarie raised their price target on Beigene from $259.00 to $313.00 and gave the stock an "outperform" rating in a research report on Friday, February 28th. Bank of America raised shares of Beigene from a "neutral" rating to a "buy" rating and lifted their price objective for the stock from $207.00 to $320.00 in a research note on Monday, March 3rd. Royal Bank of Canada initiated coverage on shares of Beigene in a research note on Monday. They issued an "outperform" rating and a $312.00 target price on the stock. Finally, JMP Securities set a $348.00 price target on shares of Beigene in a research note on Friday, February 28th.

Beigene Company Profile

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.